Lactobacillus reuteri to inhibit cryptosporidiosis in mammals

Details Lactobacillus reuteri to inhibit cryptosporidiosis in mammals Lactobacillus reuteri to inhibit cryptosporidiosis in mammals

1997-06-23

2000-08-15

Lankford, Jr., Leon B.

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Bacteria or actinomycetales

4352529, A01N 6300

Patent

active

061032271

ABSTRACT:
Cryptosporidium parvum (the cause of cryptosporidiosis) has become one of the most common enteropathogens causing diarrhea worldwide. Symptoms associated with cryptosporidiosis are very debilitating especially in the immunocompromised subject (e.g., AIDS patient). Clinical features include severe, chronic diarrhea, abdominal cramps, fatigue, weight loss, etc. which lead to increased health care costs and increased mortality. There is disclosed herein a method of inhibiting the severity of Cryptosporidium parvum infection by enterally administering a therapeutically effective amount of Lactobacillus reuteri.

REFERENCES:
patent: 5352586 (1994-10-01), Dobrogosz et al.
patent: 5800813 (1998-09-01), Casas
Axelsson et al. Microb. Ecol. in Health and Disease 2:131-136, 1989.
Alak et al. Faseb J. 10(3):A796, 1996.
Alak et al., Gastroenterology 110 (4 Suppl):A852, 1996.
Argenzio, Advances in Swine in Biomedical Res., ed. Tumbleson & Schook, Plenum Press, 1996.
Gomez et al., J. Nutr. 125:2325-2332, 1995.

Affiliated with

Also associated with

Rating

Lactobacillus reuteri to inhibit cryptosporidiosis in mammals does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lactobacillus reuteri to inhibit cryptosporidiosis in mammals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactobacillus reuteri to inhibit cryptosporidiosis in mammals will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2003680